p r e s e n t a t i o n
play

P R E S E N T A T I O N O C T O B E R 2 0 1 8 WHO ARE WE? A - PowerPoint PPT Presentation

Aug 13, 2023 •161 likes •432 views

C O M P A N Y P R E S E N T A T I O N O C T O B E R 2 0 1 8 WHO ARE WE? A MEDICAL IMAGING COMPANY WITH ULTRASOUND TECHNOLOGY Unrivaled innovative technology Strategic focus for ultrafast acquisitions and wholly software- Clinical:

  1. C O M P A N Y P R E S E N T A T I O N O C T O B E R 2 0 1 8

  2. WHO ARE WE? • A MEDICAL IMAGING COMPANY WITH ULTRASOUND TECHNOLOGY Unrivaled innovative technology Strategic focus for ultrafast acquisitions and wholly software- ‒ Clinical: Breast and Liver based image formation ‒ Geographic: China, France, United States 54 countries 172 employees 23 Aixplorer product approved including 100 in France patent families Revenue and Cumulative Installed Base 1,900 30 000 1,600 2 000 1,300 25 000 1,000 773 1 500 20 000 541 15 000 209 352 1 000 10 000 64 500 5 000 0 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Cumulative Installed Base Revenue 2 SOURCE: COMPANY

  3. OUR MISSION To become the standard in non-invasive care pathways for breast and liver diseases 3

  4. INNOVATION IN RESPONSE TO A CLINICAL CHALLENGE • A PROVEN TECHNOLOGICAL ADVANCE UltraFast TM Doppler Significantly improved patient throughput THERAPY (15 min vs. 50 min for vascular SCREENING DIAGNOSIS MONITORING examination) • MEASUREMENT OF A NEW UltraFast™ Imaging Real time ShearWave Elastography (SWE™) PARAMETER Up to Real-time, quantitative, any - Tissue stiffness (objective, transducer and any organ 20,000 images/sec reproducible, quantit.) - Replaces manual palpation • NO IONIZING RADIATION Angio PL.U.S. – Planewave ultrasensitive Doppler • NON-INVASIVE EXAMINATION Low flow rates in microvessels without contrast agents • IMPROVED PATIENT THROUGHPUT NEW! TriVu • ULTRAFAST ACQUISITION Real time B,SWE, Col+ simultaneous • 3D ACQUISITION Real-time combination Anatomy and Function 4 SOURCE: COMPANY

  5. HIGH CLINICAL ADDED VALUE FOR A GROWING USER BASE Cumulative total of publications with • GROWING BASE OF CLINICAL DATA Aixplorer 600 (+500 PUBLICATIONS IN PEER-REVIEWED JOURNALS) 500 • EXCELLENT WORLDWIDE NETWORK OF KEY OPINION LEADERS (KOL) 400 • SWE INCORPORATED IN CLINICAL GUIDE 300 LINES (BREAST AND LIVER) 200 • SWE REIMBURSED IN MANY COUNTRIES • VERY POSITIVE FEEDBACK CONCERNING 100 EASE OF USE 0 • MULTIPLE AND REPEAT SALES AT SAME SITE 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 AFTER INITIAL PURCHASE Transformation • HIGH CLINICAL VALUE OF THE TECHNOLOGY RECOGNIZED BY THE FDA : 510K CLEARANCE Technological Innovation FOR LIVER DISEASES , INCLUDING FIBROSIS AND STEATOSIS Clinical Innovation 5 SOURCE: COMPANY

  6. LOCATIONS AND PARTNERSHIP • MORE THAN 2,000 AIXPLORER SYSTEMS INSTALLED WORLDWIDE AND NUMEROUS PRESTIGIOUS PARTNERS 20% 52% 28% Americas/ EMEA Americas EMEA APAC APAC 390 systems 980 systems 530 systems (o/w 280 in the US) (o/w 380 in France) (o/w >390 in China) • CREATION OF A W FOE IN SHANGHAI • CLINICAL ASSESSMENT OF BREAST AND LIVER IN CHINA • CANADA AND • PRESENCE IN KOREA, MEXICO TAIW AN, HONG KONG SENT FROM THE US • SWITZERLAND, ITALY AND ISRAEL UNDERGOING GROW TH 6

  7. FOCUS • CLINICAL APPLICATIONS ADDRESSING MAJOR PUBLIC HEALTH NEEDS BROAD CLINICAL EXCELLENCE BREAST CANCER • • LEADING CAUSE OF CANCER IN SPECIFICITY OF DIAGNOSIS: BENIGN/MALIGNANT WOMEN: 1 IN 8 WOMEN • OBJECTIVITY OF DIAGNOSIS: NOT OPERATOR DEPENDENT • INCREASE IN NUMBER OF CANCERS: • NO RADIATION • - contraception MONITORING (EVOLUTION OF TUMORS) • SCREENING OF DENSE BREASTS - obesity (>35% WORLD POPULATION) - physical inactivity • SIGNIFICANT DECREASE IN UNNECESSARY BIOPSIES ( -47%)* LIVER DISEASES • SPECIFICITY OF DIAGNOSIS: STAGING OF FIBROSIS • HEP. B & C – FIBROSIS • INTERVENTIONAL IMAGING FOR BIOPSIES - 700 million people • CANCER SCREENING: BENIGN/MALIGNANT - Increasing (diabetes, obesity) • NON-INVASIVE FIBROSIS EVALUATION (HEP B & C) • NAFLD – STEATOSIS • STEATOSIS (NASH) DETECTION - 420 million people • REDUCTION IN USE OF CONTRAST AGENTS (ANGIO PL.U.S) - Increasing fast • LIVER CANCER Screening Diagnosis Monitoring 7 (*): CLINICAL STUDY BE1

  8. CONTINUUM OF LIVER DISEASES Attenuation Angio SWE SWE UFD SWE Speed of sound PLUS Transplantation Viscosity SWE Liver failure Portal hypertension Angio Healthy liver Simple NASH Fibrosis Cirrhosis PLUS Hepatocellular (Steatohepatitis) steatosis SWE carcinoma Inflammation, ballooning PUSH FROM PHARMA COMPANIES CRITICAL CARE PREVENTION NASH THERAPIES ANTIVIRAL THERAPIES  Imaging and treatment of   Evaluation of liver Early detection of non-  Diagnosis of liver fibrosis hepatocellular carcinoma (HCC) steatosis alcoholic fatty liver  Prediction of cirrhosis  Detection and treatment of disease (NAFLD)  Detection of complications complications (ascites, PTH, inflammation & etc.)  Selection of patients for ballooning treatment  Selection of patients for  Diagnosis and transplantation  Management and evaluation of monitoring of patients  Management and monitoring of NASH patients GENERALIST HEPATOLOGY GASTROENTEROLOGY RADIOLOGY 8

  9. A TEC H N OLOGY TH AT C AN BE R EPLIC ATED IN OTH ER C LIN IC AL APPLIC ATION S New cutting-edge technological advances Principal clinical indications for targeted applications Perfusion Perfusion  Visualization and evaluation of  Beyond conventional Doppler without use microvasculature of contrast agents  Diagnosis of hepatic lesions without use of a contrast agent Breast Vascular Vascular  Measurement of pulse wave velocity  Simultaneous indicating vascular elasticity imaging and  Improved work flow for quantifying quantification blood flow rate for better evaluation of cardiovascular diseases Liver Prostate  Better analysis of nodules during early diagnosis  SWE helps to target prostate biopsies to reduce false negatives Musculoskeletal Prostate Musculoskeletal  Real-time visualization of anatomy and functional image of muscle and   Improved Improved tendons biopsy diagnosis guidance 9

  10. F I N A N C I A L D A T A

  11. SOLID GROWTH IN 2017 In thousands of euros 2017 2016 Change (%) • +11% sales growth (+13% constant Products 21,827 20,073 +9% currency) Services 2,869 2,143 +34% • Strong product (+10%*) and service (+35%*) TOTAL SALES 24,695 22,217 +11% performance SALES GEOGRAPHIC DISTRIBUTION 2017 2016 • Tremendous growth in china (+33%*) and France (+16%) 12 000 12 000 10 816 10 310 9 579 10 000 10 000 8 192 8 000 8 000 • 18%* decline in the United States 6 000 6 000 4 446 3 569 4 000 4 000 • Asia and EMEA regions improved 2 000 2 000 respectively by +29%* and +13% over the 0 0 EMEA Americas Asia EMEA Americas Asia year 10 000 9 000 8 905 7 969 9 000 8 000 7 487 • Direct sales, which include China, France 8 000 7 000 5 797 7 000 6 000 and the United States, represent 64% of 6 000 5 104 4 403 5 000 4 048 5 000 sales revenues in 2017, against 64% in 4 000 4 000 3 199 3 000 3 000 2016 2 000 2 000 1 000 1 000 0 0 France United China RoW France United China RoW States States (*) =% at constant rate 11

  12. 9 MON TH S 2018: STABLE SALES In thousands of euros 9M 2018 9M 2017 Var. (%)  At constant exchange rates, sales grew by +3% Products 13,862 14,709 -6% over 9M 2018 % of total revenue 84% 88%  Buoyant growth in China (the Group’s largest Services 2,696 2,027 +33% market) (+32%*) and in the United States (+16%*) % of total revenue 16% 12%  Services exceeded a million euros in Q3, giving TOTAL SALES 16,558 16,737 -1% growth of +31% SALES GEOGRAPHIC DISTRIBUTION 1 st sales of the new Aixplorer MACH 30  9M 2018 9M 2017 9 000 8 334 8 000 7 442 6 969 8 000 7 000  Strong momentum expected in Q4 supported by 7 000 6 000 5 805 sales of Aixplorer MACH 30 6 000 5 000 5 000 4 000 4 000 3 000 2 325 2 419 3 000 2 000 2 000 1 000 1 000 0 0 EMEA Amériques Asie EMEA Amériques Asie 8 000 7 000 7 017 5 925 7 000 6 000 5 236 6 000 5 426 5 000 5 000 3 525 4 000 4 000 3 000 3 000 2 051 2 218 1 897 2 000 2 000 1 000 1 000 0 0 France Etats-Unis Chine RdM France Etats-Unis Chine RdM (*)= % at constant rate 12

Recommend

More recommend